Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

PIK3CA-related Overgrowth Spectrum (PROS) Clinical Trial

— EPIK-P3  

Official title:

A Phase II Study to Evaluate the Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04980833
• Other study ID #: CBYL719F12401
• Secondary ID: 2020-005896-12
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: January 27, 2022
• Est. completion date: September 1, 2027

Study information

• Verified date: March 2024
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective interventional Phase II multi center study, open label, preceded by a retrospective non-interventional period, to assess the long-term safety and efficacy of alpelisib, in pediatric and adult participants with PROS.

Description:

The study will enroll males and females aged ≥2 years who previously participated in EPIK-P1 study and who continued to receive treatment with alpelisib after the cut-off date used in EPIK-P1 (NCT04285723). The study has an initial retrospective period and a subsequent prospective period. The retrospective period, is a non-interventional study period and will start one day after the EPIK-P1 data cut-off date (i.e. 10-Mar-2020). It will end the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Key safety and efficacy information that was previously collected as per local medical practice and recorded in the medical charts of eligible participants will be longitudinally abstracted. The prospective period, is an interventional study period and will start on the day of the first interventional dose administration in the prospective period. It will end after all participants have completed at least 5 years of treatment in the prospective period of the study or discontinued earlier, whichever occurs earlier. During this study period, safety and efficacy data will be prospectively collected following a structured plan that is common to all participants.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 41
• Est. completion date: September 1, 2027
• Est. primary completion date: August 5, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

• Participants who had previously participated in the study EPIK-P1.
• Signed informed consent form and assent (when applicable) from the participant, parent, or guardian must be obtained prior to any study related screening procedures being performed.
• Participant is treated with at least one dose of alpelisib after the EPIK-P1 study data cut- off date of 09-Mar-2020. Exclusion Criteria: For participants in the retrospective period
• All EPIK-P1 participants who permanently discontinued the investigational drug on or prior to the cut-off date 09-Mar-2020. For participants in the prospective period
• Previous alpelisib treatment discontinuation (after 09-Mar-2020) due to any of the

following adverse events:

• Grade 4 skin and subcutaneous tissue disorders
• Stevens-Johnson-Syndrome (SJS)/ Toxic Epidermal Necrolysis (TEN) or other SJS/TEN-like severe skin reactions (any grade)
• Grade 4 hyperglycemia without confounding factors
• Pneumonitis (any grade)
• Grade 4 stomatitis
• Grade 4 pancreatitis
• Recurrent grade 4 thrombocytopenia
• Grade 3 or 4 serum creatinine increase
• Grade 4 isolated total bilirubin elevation
• Recurrent grade 3 or 4 QT interval corrected by Fridericia's formula prolongation (>500 ms or >60 ms change from baseline)
• Known impairment of GI function due to concomitant disease that may significantly alter the absorption of the study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) at time of informed consent.
• Participant with uncontrolled diabetes mellitus (Type I or II) at time of informed consent. Other inclusion/exclusion criteria may apply

Related Conditions & MeSH terms

• PIK3CA-related Overgrowth Spectrum (PROS)

Intervention

Drug:
• Alpelisib
Participant's treatment plan has been established by the treating physician, within the global compassionate use framework. Doses permitted are 50, 125, 200 and 250 mg.

Locations

Country	Name	City	State
France	Novartis Investigative Site	Dijon
France	Novartis Investigative Site	Montpellier Cedex
France	Novartis Investigative Site	Paris 15
Ireland	Novartis Investigative Site	Dublin
Spain	Novartis Investigative Site	Madrid
United States	Boston Childrens Hospital .	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  France,  Ireland,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prospective period only: Proportion of participants with new or worsening grade =3 treatment emergent adverse events (AEs)	Incidence of new or worsening grade =3 treatment emergent AEs (by system organ class and preferred term)	From date of first interventional dose administration in the prospective period (Day 1) to 30 days after last dose of study drug, assessed up to 5 years.
Secondary	Retrospective period: Proportion of participants with Adverse Events (AEs)	Incidence, type and severity per common terminology criteria for AEs (CTCAE) v4.03 criteria, causality assessments of AEs, including changes in laboratory values, vital signs and assessment of cardiac function during the retrospective period.	From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1)
Secondary	Prospective period: Proportion of participants with AEs	Incidence, type and severity per CTCAE v4.03 criteria, causality assessments of AEs, including changes in laboratory values, vital signs, assessment of cardiac function, and growth, sexual maturation and bone/dental development (for applicable age) during the prospective period.	From Day 1 up to 5 years
Secondary	Retrospective and prospective period: Overall clinical assessment as assessed by the investigator	Proportion of participants with overall clinical assessment reported as improvement, stable or worsened, as assessed by the investigator.	Retrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years
Secondary	Retrospective and prospective period: Incidence of PROS-related symptoms and complications/comorbidities among participants with symptoms and complications/comorbidities.	Incidence of symptoms and complications/comorbidities (including taken treatment measures) associated with PROS over time among participants with symptoms and complications/comorbidities.	Retrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years
Secondary	Retrospective and prospective period: Proportion of participants with healthcare visits/hospitalizations due to PROS.	Proportion of participants with healthcare visits/hospitalizations due to PROS will be assessed.	Retrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years
Secondary	Retrospective and prospective period: Proportion of participants requiring PROS-related treatment(s) other than alpelisib	Proportion of participants requiring PROS-related treatment(s) other than alpelisib, including medications (concomitant PROS-related medications including medication for the management of PROS related complications as well as medications to manage complications secondary to alpelisib) and non-drug treatments (e.g., feeding tube, ketogenic diet, non-invasive device for sleep apnea, sclerotherapy, endovascular occlusive procedures)	Retrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years
Secondary	Retrospective and prospective period: Proportion of participants with dose adjustments of alpelisib	Proportion of participants requiring dose increase, reductions and interruptions of alpelisib	Retrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years
Secondary	Retrospective and prospective period: Proportion of participants with PROS-related surgeries	Proportion of participants requiring surgery due to PROS	Retrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years